The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing amiodarone, reached the following conclusions.
Considering the available data from the literature and spontaneous reports, including the chronology of the interaction between amiodarone and sirolimus leading to increased toxicity of sirolimus, PRAC considers that the aggregate data are sufficient to confirm a causal relationship. PRAC concluded that the instructions for medical use of medicinal products containing amiodarone should be amended accordingly.
In view of the available data from the literature and spontaneous reports, the PRAC considers that a causal relationship between the use of medicinal products containing amiodarone and the occurrence of such adverse reactions as hallucinations, neutropenia, agranulocytosis, and decreased libido is at least possible. The PRAC concluded that the instructions for medical use of medicinal products containing amiodarone should be amended accordingly.
The Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the PRAC scientific conclusions.
Based on the scientific conclusions, the CMDh considers that the benefit/risk balance of medicinal products containing amiodarone (amiodarone) remains unchanged, provided that changes are made to the instructions for medical use.
Amendments to be included in the relevant sections of the package insert (new text underlined in bold, deleted text struck through).
Section "Interaction with other medicinal products and other forms of interaction"
The interaction should be added as follows:
Substrates of CYP P450 3A4
Other medicinal products metabolized by cytochrome P450 3A4: lidocaine, sirolimus, tacrolimus, sildenafil, fentanyl, midazolam, triazolam, dihydroergotamine, ergotamine and colchicine.
“Adverse reactions” section
The adverse reaction “Decreased libido” should be added to the “Psychiatric disorders” section with the frequency “Common”.
The adverse reaction “Hallucinations” should be added to the “Psychiatric disorders” section with the frequency “Not known”.
The adverse reactions “Neutropenia” and “Agranulocytosis” should be added to the section “Blood and lymphatic system disorders” with the frequency “Not known”
Перелік лікарських засобів, що містять аміодарон (amiodarone) і дозволені до медичного застосування в Україні (за даними Державного реєстру лікарських засобів України станом на 05.11.2021).
To analyze the published information, the applicant must use the original text available at the linkhttps://www.ema.europa.eu/documents/psusa/amiodarone-scientific-conclusions-grounds-variation-terms-marketing-authorisation-psusa-00000166_en.pdf